Shuoshe Biology: In 2025, the revenue was 340 million yuan, and the net loss was 39.71 million yuan.

Shuoshi Biology announced that in 2025, the total operating income was 340.38 million yuan, a year-on-year decrease of 2.64%; the net profit attributable to the owners of the parent company was -39.71 million yuan, an increase in losses of 37.71 million yuan. At the end of the reporting period, the total assets were 3.55 billion yuan, a decrease of 4.98% compared to the beginning of the period; the owner's equity attributable to the parent company was 2.92 billion yuan, a decrease of 9.87% compared to the beginning of the period. The main reasons for the performance changes were industry competition, centralized procurement of medical products, a decrease in provision for impairment of accounts receivable, provision for asset impairment, and a decrease in government subsidies. In addition, due to the implementation of equity distribution in June 2025, the share capital increased by 48.00% year-on-year.